

Intellia Therapeutics, Inc.
Form 8-K
September 01, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Act of 1934

Date of Report (Date of earliest event reported): **August 30, 2017**

INTELLIA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

| | | |
|---|--|--|
| Delaware (State or other jurisdiction | 001-37766 (Commission | 36-4785571 (I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| 40 Erie Street, Suite 130, | | |
| Cambridge, Massachusetts (Address of principal executive | 02139 (Zip Code) | |
| offices) | | |

Registrant's telephone number, including area code: (857) 285-6200

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Edgar Filing: Intellia Therapeutics, Inc. - Form 8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02(b). Departure of Certain Officers.

On August 30, 2017, Nicole Heifner, Senior Vice President, Accounting (and principal accounting officer) of Intellia Therapeutics, Inc. (the Company) informed the Company that she will be resigning from her position effective September 15, 2017 to pursue other employment opportunities. Ms. Heifner's resignation was not related to any disagreements with the Company on any matter relating to its operations, policies, practices or any issues regarding financial disclosures, accounting or legal matters.

Graeme Bell, Intellia's Executive Vice President and Chief Financial Officer, will fulfill the duties of principal accounting officer until a permanent successor is appointed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 1, 2017

Intellia Therapeutics, Inc.

By: /s/ Nessian Bermingham
Nessian Bermingham, Ph.D.
President and Chief Executive Officer